Página Web informativa sobre HoLEP

Dr. José Placer

© José Placer

Enero 2019

Formación académica

• Licenciado en Medicina y Cirugía por la Universidad de Cantabria (1997)     

• Especialista en Urología (2004)

• Doctor en Cirugía por la Universitat Autònoma de Barcelona (2005)

• Profesor Asociado de Urología de la Universitat Autònoma de Barcelona (2006-2010)

Actividad profesional

• Médico interno residente en Urología en el Hospital del Mar - Hospital de l’Esperança de Barcelona (1999-2004)     

• Médico adjunto especialista en Urología del Hospital del Mar - Hospital de l’Esperança de Barcelona (2004-2008)

• Médico adjunto especialista en Urología del Hospital Universitari Vall d’Hebron de Barcelona (desde 2008)

• Médico asociado especialista en Urología del Hospital Quirón - Dexeus de Barcelona (desde 2008)

Principales áreas de interés

• Hiperplasia benigna de próstata     

• Cirugía del adenoma prostático

• Cirugía prostática con láser

• Trasplante renal

Pertenencia a asociaciones profesionales

• Asociación Española de Urología (desde 2001)     

• European Association of Urology (desde 2007)

• Colegiado en el Col.legi Oficial de Metges de Barcelona (nº 33924) desde 1999

Últimas publicaciones científicas

1. Morote J, Comas I, Planas J, Maldonado X, Celma A, Placer J, Ferrer R, Carles J, Regis L. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy. Clin Genitourin Cancer 2018,16(2):e491-e496


2. Lorente D, Trilla E, Meseguer A, Planas J, Placer J, Celma A, Salvador C, Regis L, Morote J. Systematic review of renal carcinoma prognostic factors. Actas Urol Esp 2017,41(4):215-225


3. Trilla E, Konstantinidis C, Serres X, Lorente D, Planas J, Placer J, Salvador C, Celma A, Montealegre C, Morote J. Ultrasound-guided percutaneous radiofrequency ablation for treating small renal masses. Actas Urol Esp 2017,41(8):497-503


4. Morote J, Celma A, Planas J, Placer J, Ferrer R, de Torres I, Pacciuci R, Olivan M. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study. Actas Urol Esp 2016,40(6):378-385


5. Planas J, Celma A, Placer J, Cuadras M, Regis L, Gasanz C, Trilla E, Salvador C, Lorente D, Morote J. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer. Scand J Urol 2016,50(6):425-428


6. Planas J, Celma A, Placer J, Maldonado X, Trilla E, Salvador C, Lorente D, Regis L, Cuadras M, Carles J, Morote J. Hormonal changes after localized prostate cancer treatment. Comparison between external beam radiation therapy and radical prostatectomy. Actas Urol Esp 2016,40(9):549-555


7. Servian P, Celma A, Planas J, Placer J, de Torres IM, Morote J. Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies. Prostate 2016,76(16):1501-1506


8. Ferrándiz-Pulido C, Hernández-Losa J, Masferrer E, Vivancos A, Somoza R, Marés R, Valverde C, Salvador C, Placer J, Morote J, Pujol RM, Ramon y Cajal S, de Torres I, Toll A, García-Patos V. Identification of somatic gene mutations in penile squamous cell carcinoma. Genes Chromosomes Cancer 2015,54(10):629-637


9. Olivan M, Rigau M, Colás E, Garcia M, Montes M, Sequeiros T, Regis L, Celma A, Planas J, Placer J, Reventós J, de Torres I, Doll A, Morote J. Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell lines. Biomed Res Int 2015,2015:762178


10. Placer J, Planas J, Celma A, Morote J. [Current role of protatic specific antigen (PSA) and its by-products in the diagnosis of prostate cancer]. Arch Esp Urol 2015,68(3):210-228


11. Placer J, Salvador C, Planas J, Trilla E, Lorente D, Celma A, López MÁ, Morote J. Effects of holmium laser enucleation of the prostate on sexual function. J Endourol 2015,29(3):332-339


12. Sequeiros T, Bastarós JM, Sánchez M, Rigau M, Montes M, Placer J, Planas J, de Torres I, Reventós J, Pegtel DM, Doll A, Morote J, Olivan M. Urinary biomarkers for the detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Prostate 2015,75(10):1102-1113


13. Servian P, Celma A, Planas J, Placer J, de Torres IM, Olivan M, Morote J. Clinical significance of proliferative inflammatory atrophy finding in prostatic biopsies. Prostate 2015,75(14):1669-1675


14. Trilla E, Lorente D, Salvador C, Planas J, Placer J, Celma A, Cantarell C, Moreso F, Seron D, Morote J. Native ureteropyelostomy in the treatment of obstructive uropathy in adult renal transplant. Experience and technical alternatives. Actas Urol Esp 2014,38(8):552-556


15. Bastarós J, Placer J, Celma A, Planas J, Morote J. Current significance of the finding of high grade prostatic intraepithelial neoplasia in the prostate biopsy. Actas Urol Esp 2014,38(4):270-275


16. Celma A, Servián P, Planas J, Placer J, Quilez MT, Arbós MA, de Torres I, Morote J. Clinical significance of proliferative inflammatory atrophy in prostate biopsy. Actas Urol Esp 2014,38(2):122-126


17. Morote J, Celma A, Planas J, Placer J, de Torres I, Olivan M, Carles J, Reventós J, Doll A. Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. Int J Mol Sci 2014,15(8):13615-13623


18. Morote J, Celma A, Planas J, Placer J, Konstantinidis C, Iztueta I, de Torres IM, Oliván M, Reventós J, Doll A. Sedentarism and overweight as risk factors for the detection of prostate cancer and its aggressivenes. Actas Urol Esp 2014,38(4):232-237


19. Morote J, Ropero J, Planas J, Celma A, Placer J, Ferrer R, de Torres I. Metabolic syndrome in patients with prostate cancer undergoing androgen suppression. Actas Urol Esp 2014,38(5):285-289


20. Salvador C, Planas J, Agreda F, Placer J, Trilla E, Lopez MA, Morote J. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. Urol Int 2013,90(1):41-44


21. Morote J, Ropero J, Planas J, Bastarós JM, Delgado G, Placer J, Celma A, de Torres IM, Carles J, Reventós J, Doll A. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int 2013,111(7):1031-1036


22. Menéndez V, Fernández-Suárez A, Placer J, García-Linares M, Tarragon S, Liso E. Dhat syndrome, an emergent condition within urology in Spain. World J Urol 2013,31(4):941-945


23. Masferrer E, Ferrándiz-Pulido C, Lloveras B, Masferrer-Niubò M, Espinet B, Salido M, Rodríguez-Rivera M, Alemany L, Placer J, Gelabert A, Servitje O, García-Patos V, Pujol RM, Toll A. MYC copy number gains are associated with poor outcome in penile squamous cell carcinoma. J Urol 2012,188(5):1965-1971


24. Salvador C, Planas J, Raventós C, Ropero J, Placer J, López MA, Morote J. [Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients]. Actas Urol Esp 2012,36(4):205-209


25. Placer J, Morote J. Re: Endo et al.: Anteroposterior dissection HoLEP: a modification to prevent transient stress urinary incontinence (Urology 2010;76:1451-1455). Urology 2011,77(1):255-6; author reply 256


26. Placer J, Morote J. [Usefulness of prostatic specific antigen (PSA) for diagnosis and staging of patients with prostate cancer]. Arch Esp Urol 2011,64(8):659-680


27. Placer J, López MA, Raventós C, Planas J, Salvador C, Ropero J, Morote J. [Holmium laser enucleation of the prostatic adenoma]. Arch Esp Urol 2011,64(3):246-256


28. Placer J. [Comment to: “Enucleation of the prostate with 980 mm diode laser (Dilep): technique and initial results”]. Actas Urol Esp 2011,35(1):42-43


29. Galván AB, Salido M, Espinet B, Placer J, Pijuan L, Juanpere N, Lloreta J, Solé F, Gelabert-Mas A. A multicolor fluorescence in situ hybridization assay: A monitoring tool in the surveillance of patients with a history of non-muscle-invasive urothelial cell carcinoma: A prospective study. Cancer Cytopathol 2011,119(6):395-403


30. del Rey J, Placer J, Vallmanya F, Pujol N, Prat E, Miró R, Gelabert A. Are patients with non-muscle-invasive bladder cancer a suitable population for a lung cancer screening trial. BJU Int 2010,106(1):49-52


31. Morote J, Planas J, Ramirez C, Gómez E, Raventós CX, Placer J, Catalán R, de Torres IM. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. BJU Int 2010,105(4):481-484


32. Morote J, Rigau M, Garcia M, Mir C, Ballesteros C, Planas J, Raventós CX, Placer J, de Torres IM, Reventós J, Doll A. Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. World J Urol 2010,28(6):677-680


33. Placer J, Gelabert-Mas A, Vallmanya F, Manresa JM, Menéndez V, Cortadellas R, Arango O. Holmium laser enucleation of prostate: outcome and complications of self-taught learning curve. Urology 2009,73(5):1042-1048


34. Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int 2009,104(11):1637-1640


35. Vallmanya F, Placer J, Pou Serradell A, Cortadellas R, Gelabert-Mas A. Tuberous sclerosis complex. Forty-years of follow-up of a patient affected. Arch Esp Urol 2006,59(1):105-107


36. Salido M, Lloreta J, Melero C, García M, Placer J, Espinet B, Villa O, Bielsa O, Gelabert-Mas A, Serrano S, Solé F. Insertion (8;11) in a renal oncocytoma with multifocal transformation to chromophobe renal cell carcinoma. Cancer Genet Cytogenet 2005,163(2):160-163


37. Placer J, Espinet B, Salido M, Solé F, Gelabert-Mas A. Correlation between histologic findings and cytogenetic abnormalities in bladder carcinoma: a FISH study. Urology 2005,65(5):913-918


38. Lorente Garín JA, Placer Santos J, Salvadó Costa M, Segura Alvarez C, Gelabert-Mas A. [Antibiotic resistance transformation in community-acquired urinary infections]. Rev Clin Esp 2005,205(6):259-264


39. Placer J, Cortadellas R, Grases F, Gelabert-Mas A. Fecal and urinary obstruction by a stone in ureterosigmoidostomy. J Urol 2003,170(2 Pt 1):516


40. Placer J, Espinet B, Salido M, Solé F, Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 2002,42(6):547-552

Dr. José Placer 2

Dr. José Placer